产品
编 号：F434742
分子式：C19H20N4O2
分子量：336.39
分子式：C19H20N4O2
分子量：336.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 714272-27-2
产品详情
生物活性：
Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells.
体内研究：
PlinabuLin (0 mg/kg-15 mg/kg；腹膜内注射；雌性 CDF1 和 C3H/He 小鼠) 诱导肿瘤灌注的时间和剂量依赖性降低。KHT 肉瘤比 C3H 肿瘤对 Plinabulin 的抗肿瘤作用更敏感，而两种模型的放射反应均得到增强。Animal Model:Female CDF1 mice (10-14-week-old) with C3H mammary carcinoma; Female C3H/HeJ mice with KHT sarcoma cells (8-weeks-old)
Dosage:0 mg/kg, 1.5 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 12.5 mg/kg, 15 mg/kg;0.02 mL/g mouse body weight in CDF1 mice and 0.01 mL/g body weight for C3H/HeJ mice
Administration:Intraperitoneal injection; 0 huor, 1 huor, 3 hours, 6 huors, 24 huors
Result:Induced a time- and dose-dependent decrease in tumour perfusion. The KHT sarcoma was more sensitive than the C3H tumour to the anti-tumor, while radiation response was enhanced in both models.
体外研究：
PlinabuLin (NPI-2358) (2 -200 nM；30 分钟；HUVECs 细胞) 是一种有效的抗肿瘤剂，在多重耐药 (MDR) 肿瘤细胞系中具有活性，能够快速诱导微管蛋白解聚和单层通透性在 HUVEC 中，DU 145 细胞的 IC50 值为 18 nM；PC-3 细胞为 13 nM；MDA-MB-231 细胞为 14 nM；NCI-H292 细胞为 18 nM；Jurkat 白血病细胞为 11 nM。
Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells.
体内研究：
PlinabuLin (0 mg/kg-15 mg/kg；腹膜内注射；雌性 CDF1 和 C3H/He 小鼠) 诱导肿瘤灌注的时间和剂量依赖性降低。KHT 肉瘤比 C3H 肿瘤对 Plinabulin 的抗肿瘤作用更敏感，而两种模型的放射反应均得到增强。Animal Model:Female CDF1 mice (10-14-week-old) with C3H mammary carcinoma; Female C3H/HeJ mice with KHT sarcoma cells (8-weeks-old)
Dosage:0 mg/kg, 1.5 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 12.5 mg/kg, 15 mg/kg;0.02 mL/g mouse body weight in CDF1 mice and 0.01 mL/g body weight for C3H/HeJ mice
Administration:Intraperitoneal injection; 0 huor, 1 huor, 3 hours, 6 huors, 24 huors
Result:Induced a time- and dose-dependent decrease in tumour perfusion. The KHT sarcoma was more sensitive than the C3H tumour to the anti-tumor, while radiation response was enhanced in both models.
体外研究：
PlinabuLin (NPI-2358) (2 -200 nM；30 分钟；HUVECs 细胞) 是一种有效的抗肿瘤剂，在多重耐药 (MDR) 肿瘤细胞系中具有活性，能够快速诱导微管蛋白解聚和单层通透性在 HUVEC 中，DU 145 细胞的 IC50 值为 18 nM；PC-3 细胞为 13 nM；MDA-MB-231 细胞为 14 nM；NCI-H292 细胞为 18 nM；Jurkat 白血病细胞为 11 nM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备